EQRX, Inc.

Clinical trials sponsored by EQRX, Inc., explained in plain language.

Now part of Revolution Medicines, Inc. RVMD NASDAQ

Clinical-stage biopharma developing precision oncology therapies.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Terminated 1

New drug combo for advanced breast cancer shows promise but trial halted early

Disease control Stopped early

This phase 2 study tested a new drug called lerociclib combined with standard hormone therapy in 100 people with advanced HR+/HER2- breast cancer. The goal was to see if the combination is safe and effective. However, the trial was terminated early, so the full results are not av…

Phase 2 • Sponsor: EQRx, Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:34 UTC

EQRX, Inc.

New drug combo for advanced breast cancer shows promise but trial halted early